logo-loader

Imugene's Leslie Chong says positive HER-Vaxx data 'validates entire platform'

Published: 15:43 23 Nov 2020 AEDT

Imugene Limited’s (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong tells Proactive's Andrew Scott she's delighted with what the interim data has revealed in their ongoing randomised Phase 2 study of HER-Vaxx in gastric cancer. It's shown positive overall survival with a Hazard Ratio of 0.418. The median overall survival for patients receiving HER-Vaxx plus chemotherapy was 14.2 months, compared to 8.8 months in patients treated with chemotherapy alone. Chong says they're now assessing how best to take development of the drug forward.

Imugene progresses onCARlytics solid tumour trial to combination arm

Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong joins Proactive’s Jonathan Jackson in the Proactive studio to discuss how the company has advanced its Phase 1 onCARlytics solid tumour trial to combination arm treatment. The trial, known as OASIS, focuses on adult patients with advanced or...

1 week, 1 day ago